Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

Key facts

Sponsor

ANRS, Emerging Infectious Diseases

Principal Investigator

Nathalie DE CASTRO, MD

AP-HP, Hôpital Saint-Louis

Intervention

Adalimumab Injection(drug)

Enrollment

130 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2027

Study locations (3)

• Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ, Rio de Janeiro, Brazil
• Instituto Nacional de Saude, Maputo, Mozambique
• Adult Infectious Diseases Centre, University Teaching Hospital, Lusaka, Zambia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for OBSOLETE: Tuberculous meningitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT05383742
  Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
  National Institute of Allergy and Infectious Diseases (NIAID)

See all trials for OBSOLETE: Tuberculous meningitis →